Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience-Reference-Cited by-同舟云学术

Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience

Published:2017-09-11 Issue:1 Volume:107 Page:69-74
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Al Askar Ahmed S.^ORCID,Shaheen Naila A.,Al Zahrani Mohsen,Al Otaibi Mohammed G.,Al Qahtani Bader S.,Ahmed Faris,Al Zughaibi Mohand,Kamran Ismat,Mendoza May Anne,Khan Altaf

Funder

King Abdullah International Medical Research Center

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

http://link.springer.com/article/10.1007/s12185-017-2325-y/fulltext.html

Reference23 articles.

1. McCrae K. Immune thrombocytopenia: no longer ‘idiopathic’. Cleve Clin J Med. 2011;78(6):358–73. doi: 10.3949/ccjm.78gr.10005 .

2. Abrahamson PE, Hall SA, Feudjo-Tepie M, Mitrani-Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review. Eur J Haematol. 2009;83(2):83–9. doi: 10.1111/j.1600-0609.2009.01247.x .

3. Schoonen WM, Kucera G, Coalson J, Li L, Rutstein M, Mowat F, et al. Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database. Br J Haematol. 2009;145(2):235–44. doi: 10.1111/j.1365-2141.2009.07615.x .

4. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005;106(7):2244–51.

5. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rituximab versus Splenectomy in Chronic Primary ITP: Experience of a Single Hematology Clinic;Mediterranean Journal of Hematology and Infectious Diseases;2024-02-29

2. Rituximab resistance in ITP and beyond;Frontiers in Immunology;2023-07-28

3. Platelet desialylation and TFH cells–the novel pathway of immune thrombocytopenia;Experimental Hematology & Oncology;2021-03-15

4. Second‐line treatments and outcomes for immune thrombocytopenia: A retrospective study with electronic health records;Research and Practice in Thrombosis and Haemostasis;2020-09-11

5. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus;Rheumatology International;2020-08-14